Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rudolf Stadler

Showing results (101-110 of 145) with videos related to

Pageof 15
Sort By:
Melanoma Research|November 14, 2023
Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNISKatharina C Kähler, Dirk Debus, Gaston Schley, et al.
Cancers|January 10, 2026
Brentuximab Vedotin in Advanced-Stage Mycosis Fungoides/Sézary Syndrome with Low CD30 Expression: Real-World Data from the German Cutaneous Lymphoma NetworkChristoph Blazejak, Mathias Oymanns, René Stranzenbach, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|August 23, 2025
Low-dose total skin electron beam therapy in erythrodermic mycosis fungoides and Sézary syndrome: Results From the Prospective S-MISR StudyKhaled Elsayad, Christian Kandler, Jan Jakob Siats, et al.
Journal of Translational Medicine|November 7, 2015
Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanomaLisa Zimmer, Thomas K Eigentler, Felix Kiecker, et al.
Blood|May 22, 2023
Dimethyl fumarate treatment in relapsed and refractory cutaneous T-cell lymphoma: a multicenter phase 2 studyJan P Nicolay, Susanne Melchers, Jana D Albrecht, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 9, 2016
Mitoserate beim primären Melanom: Interobserver- und Intraobserver-Reproduzierbarkeit am HE-Schnitt und in der ImmunhistologieClaus Garbe, Thomas K Eigentler, Jürgen Bauer, et al.
The Lancet. Oncology|May 11, 2016
Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trialUlrike Leiter, Rudolf Stadler, Cornelia Mauch, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 9, 2016
Mitotic rate in primary melanoma: interobserver and intraobserver reliability, analyzed using H&E sections and immunohistochemistryClaus Garbe, Thomas K Eigentler, Jürgen Bauer, et al.
The Journal of Pathology. Clinical Research|January 16, 2026
Alcian blue-positive stromal phenotype in basal cell carcinoma is associated with progression on first-line hedgehog inhibitorsViola K DeTemple, Rudolf Stadler, Sabine Bredemeier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2009
Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanomaAxel Hauschild, Michael Weichenthal, Knuth Rass, et al.
Pageof 15

Showing results (101-110 of 145) with videos related to

Sort By:
Pageof 15
Melanoma Research|November 14, 2023
Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNISKatharina C Kähler, Dirk Debus, Gaston Schley, et al.
Cancers|January 10, 2026
Brentuximab Vedotin in Advanced-Stage Mycosis Fungoides/Sézary Syndrome with Low CD30 Expression: Real-World Data from the German Cutaneous Lymphoma NetworkChristoph Blazejak, Mathias Oymanns, René Stranzenbach, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|August 23, 2025
Low-dose total skin electron beam therapy in erythrodermic mycosis fungoides and Sézary syndrome: Results From the Prospective S-MISR StudyKhaled Elsayad, Christian Kandler, Jan Jakob Siats, et al.
Journal of Translational Medicine|November 7, 2015
Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanomaLisa Zimmer, Thomas K Eigentler, Felix Kiecker, et al.
Blood|May 22, 2023
Dimethyl fumarate treatment in relapsed and refractory cutaneous T-cell lymphoma: a multicenter phase 2 studyJan P Nicolay, Susanne Melchers, Jana D Albrecht, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 9, 2016
Mitoserate beim primären Melanom: Interobserver- und Intraobserver-Reproduzierbarkeit am HE-Schnitt und in der ImmunhistologieClaus Garbe, Thomas K Eigentler, Jürgen Bauer, et al.
The Lancet. Oncology|May 11, 2016
Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trialUlrike Leiter, Rudolf Stadler, Cornelia Mauch, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 9, 2016
Mitotic rate in primary melanoma: interobserver and intraobserver reliability, analyzed using H&E sections and immunohistochemistryClaus Garbe, Thomas K Eigentler, Jürgen Bauer, et al.
The Journal of Pathology. Clinical Research|January 16, 2026
Alcian blue-positive stromal phenotype in basal cell carcinoma is associated with progression on first-line hedgehog inhibitorsViola K DeTemple, Rudolf Stadler, Sabine Bredemeier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2009
Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanomaAxel Hauschild, Michael Weichenthal, Knuth Rass, et al.
Pageof 15